TP53 and acute myeloid leukemia: Those with TP53 disruption/aneuploidy showed a higher risk of AML (HR 5.7, 95%CI 1.8–18.4, p = 0.004) corrected by IPSS (HR 2.0, 95%CI 1.1–3.5, p = 0.01) (see Supplemental Table S5).